Gland Pharma Ltd (NSE:GLAND)

Q3 2026 Gland Pharma Ltd Earnings Call Transcript

Jan 28, 2026 / 01:00 PM GMT

Release Date Price: ₹1689.7 (+0.82%)

Transcript

Key Points

Positve

Gland Pharma Ltd (NSE:GLAND) reported a strong quarter with a 22% year-on-year revenue growth, reaching INR 16,954 million.
The company achieved a significant improvement in profitability, with adjusted EBITDA increasing by 26% year-on-year.
Gland Pharma Ltd (NSE:GLAND) launched 10 new products in the US, contributing to a 16% year-on-year revenue growth in the US market.
The company is expanding its cartridge fill and finish capacity from 40 million to 140 million units, indicating a strong pipeline and future growth potential.
Senexi, a subsidiary of Gland Pharma Ltd (NSE:GLAND), delivered a positive EBITDA of EUR 1 million, marking a successful turnaround and contributing to the overall financial performance.

Negative

Despite the strong performance, the gross margins for the base business excluding Senexi decreased to 61% from 63% last year due to product mix.
The company faces challenges in maintaining high margins amidst pricing pressures and product mix impacts.
There is a dependency on the timely approval and launch of new products, such as the delayed US launch of a large product by a partner, which could impact revenue projections.
The expansion plans, including a significant CapEx investment of INR 2,000 crores over the next five years, carry execution risks and require careful management.
The company's growth projections are contingent on successful integration and synergy realization from the Senexi acquisition, which may take time to fully materialize.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GLAD.NS - Gland Pharma Ltd
Q3 2026 Gland Pharma Ltd Earnings Call
Jan 28, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gen

Good day and welcome to the Gland Farmer Limited, Q3S526 earnings conference call.

As a reminder

All participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions, presentation concludes.

Should you need assistance during the call, please signal an operating in star, then 0 on your touchstone phone.

I now had the conference over to Mrs.

Gnawa from the Investor relations team.

Thank you and

Over to you, sir

Thank you, Rayo.

Good evening, everyone.

We welcome you to Bland Pharma Earnings Conference call for Q3 of F 526.

I'm Shuyangi from the Investor relations Team

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.